CLAIM AMENDMENTS

1 through 9 (canceled).

10. (New) A compound selected from the group consisting of

(a) Leu Lys Ala Thr Thr Asn Ser Lys Leu Met Met Tyr (Seq ID NO: 1);
(b) Val Asp Met Ile Asn Asp Val Gln Pro Leu Thr Pro (Seq ID NO: 2);
(c) Val Asp Met Ile Asp Asp Val Gln Pro Leu Thr Pro (Seq ID NO: 3);
(d) Val Asp Met Ile Asn Asp Val Gln Pro Met Thr Pro (Seq ID NO: 4);
(e) Val Tyr Met Met Asn Asn Gly Gln Pro Pro Ser Pro (Seq ID NO: 5);
(f) Val Asp Met Ile Asn Asp Val Gln Pro Met Ser Pro (Seq ID NO: 6);
(g) Trp His Trp Gln Trp Thr Pro Trp Ser Ile Gln Pro (Seq ID NO: 7);
(h) His Ser Pro Leu Asp Ser Ser Arg His Ala Thr Tyr (Seq ID NO: 8);
(i) His Tyr Thr Leu Asp Ser Cys Arg His Pro Thr Tyr (Seq ID NO: 9);
(j) Val Tyr Ser Ser Thr Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 10);
(k) Val Tyr Ser Ser Asn Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 11);
(l) Val Tyr Ser Ser Asn Asn Arg Pro Leu Pro Ser Pro (Seq ID NO: 12);
(m) Val Tyr Leu Leu Asn Asn Arg Pro Leu Pro Ser Pro (Seq ID NO: 13);
(n) Val Tyr Leu Leu Ser Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 14);
(o) Val Tyr Trp Pro Thr Asn Arg Pro Leu Pro Ser Pro (Seq ID NO: 15);
(p) Val Gln Pro Ser Ile Asn Arn Pro His Gln Arg Pro (Seq ID NO: 16);
(q) Tyr His Asn Tyr Thr Thr Ala Pro His Ser Pro Ser (Seq ID NO: 17);
(r) Lys Pro Val Ile Ser Pro Thr Asn Ala Leu Gln Pro (Seq ID NO: 18);
(s) Val Thr Gly Pro Thr Lys Asn Leu Pro Ala Thr Thr (Seq ID NO: 19);
(t) Ala Ser His Val Asp Tyr Arg Arg Phe Leu Leu Thr (Seq ID NO: 20);
(u) Asp Gln Asp Phe Als Pro Asp Arg His Tyr Arg Leu (Seq ID NO: 21);
(v) Gln Lys Trp Pro Glu Thr Tyr Pro Asp Leu Ser Phe (Seq ID NO: 22);

(w) Gly Asp Pro Val Pro Gln Thr Tyr Ser Ala Ala Gly (Seq ID NO: 23);
(x) Ala Val Ser Val Asn Thr Lys Ile Asp Thr Glu Ala (Seq ID NO: 24);
(y) Gln Pro Asn Tyr Thr Ser Leu Leu Tyr Gly Thr Glu (Seq ID NO: 25);
(z) Thr Gln Pro Pro Ile His His Tyr Gln Leu Pro Ala (Seq ID NO: 26); and
(aa) Gly Trp Asp His Ile His Gly Val His Gln His Val (Seq ID NO: 27).

11. (New) Leu Lys Ala Thr Thr Asn Ser Lys Leu Met Met Tyr (Seq ID NO: 1) as defined in claim 10.

12. (New) Val Asp Met Ile Asn Asp Val Gln Pro Leu Thr Pro (Seq ID NO: 2) as defined in claim 10.

13. (New) His Ser Pro Leu Asp Ser Ser Arg His Ala Thr Tyr (Seq ID NO: 8) as defined in claim 10.

14. (New) Val Tyr Ser Ser Thr Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 10) as defined in claim 10.

15. (New) A pharmaceutical composition for the treatment of transmissible spongiform encephalopathy which comprises a therapeutically effective amount of the compound defined in claim 1 together with a pharmaceutically acceptable inert carrier or diluent.

16. (New) The pharmaceutical composition defined in claim 15 in solid, semiliquid or liquid form.

17. (New) The pharmaceutical composition defined in claim 15 in the form of an injection solution, drop, juice, syrup, spray, suspension, granulate, tablet, pellet, transdermal therapeutic system, capsule, plaster, suppository, salve, cream, lotion, gel, emulsion or aerosol form.

18. (New) The pharmaceutical composition defined in claim 15 further comprising an auxiliary substance selected from the group consisting of a surface active substance, a coloring agent, a preservative, a bursting agent, a smoothing agent, a lubricant, an aromatizing agent and/or a binder.

19. (New) The peptide defined in claim 10 substituted or modified by at least one component selected from the group consisting of sugar residues, glucoromic acid, sulfate residues, serine, glycine or aspartate.

20. (New) A method of making a peptide as defined in claim 10 in that a solid phase synthesis in a liquid phase is used.

21. (New) A method of making a peptide as defined in claim 10 wherein the peptide is expressed by a nucleic acid coding therefore.

22. (New) A method of inhibiting replication of a PrP^{Sc} prion in a mammalian subject which comprises the step of administering to said subject a therapeutically effective amount of the compound defined in claim 10.

23. (New) The method of inhibiting replication of a PrP^{Sc} prion in a mammalian subject defined in claim 22 wherein the mammalian subject is a human.